1. Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation
- Author
-
Vandebriel, Rob J., Stalpers, Coen A.L., Vermeulen, Jolanda P., Remkes, Mariska, Schmelter, Marit, Broere, Femke, Hoefnagel, Marcel H.N., Immunologie, Interne geneeskunde GD, CS_Welfare & emerging diseases, and Infectious Diseases and Immunology
- Subjects
Consistency approach ,Tetanus/prevention & control ,Whooping Cough ,Inflammasomes ,Aluminum Hydroxide ,Diphtheria-Tetanus-acellular Pertussis Vaccines ,Diphtheria/prevention & control ,Inflammasome ,Cell Line ,Adjuvants, Immunologic ,NLRP3 ,Adjuvants, Immunologic/pharmacology ,NLR Family, Pyrin Domain-Containing 3 Protein ,Humans ,Whooping Cough/prevention & control ,Adjuvant ,Aluminum Hydroxide/pharmacology ,Diphtheria-Tetanus-Pertussis Vaccine ,Pertussis Vaccine ,Tetanus ,General Veterinary ,General Immunology and Microbiology ,Aluminium phosphate ,Public Health, Environmental and Occupational Health ,Aluminium hydroxide ,Diphtheria ,Antibodies, Bacterial ,Infectious Diseases ,Molecular Medicine ,Aluminum - Abstract
Safety and potency assessment for batch release testing of established vaccines still relies partly on animal tests. An important avenue to move to batch release without animal testing is the consistency approach. This approach is based on thorough characterization of the vaccine to identify critical quality attributes that inform the use of a comprehensive set of non-animal tests to release the vaccine, together with the principle that the quality of subsequent batches follows from their consistent production. Many vaccine antigens are by themselves not able to induce a protective immune response. The antigens are therefore administered together with adjuvant, most often by adsorption to aluminium salts. Adjuvant function is an important component of vaccine potency, and an important quality attribute of the final product. Aluminium adjuvants are capable of inducing NLRP3 inflammasome activation. The aim of this study was to develop and evaluate an in vitro assay for NLRP3 inflammasome activation by aluminium-adjuvanted vaccines. We evaluated the effects of Diphtheria-Tetanus-acellular Pertussis combination vaccines from two manufacturers and their respective adjuvants, aluminium phosphate (AP) and aluminium hydroxide (AH), in an in vitro assay for NLRP3 inflammasome activation. All vaccines and adjuvants tested showed a dose-dependent increase in IL-1β production and a concomitant decrease in cell viability, suggesting NLRP3 inflammasome activation. The results were analysed by benchmark dose modelling, showing a similar 50% effective dose (ED50) for the two vaccine batches and corresponding adjuvant of manufacturer A (AP), and a similar ED50 for the two vaccine batches and corresponding adjuvant of manufacturer B (AH). This suggests that NLRP3 inflammasome activation is determined by the adjuvant only. Repeated freeze-thaw cycles reduced the adjuvant biological activity of AH, but not AP. Inflammasome activation may be used to measure adjuvant biological activity as an important quality attribute for control or characterization of the adjuvant.
- Published
- 2022